Matinas BioPharma
MTNB
45 hedge funds and large institutions have $27.7M invested in Matinas BioPharma in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 12 closing their positions.
4.38% less ownership
Funds ownership: 27% → 22.62% (-4.4%)
13% less funds holding
Funds holding: 52 → 45 (-7)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
75% less capital inflows, than outflows
Capital inflows: $1.88M | Capital outflows: $7.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.36M |
| 2 |
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
+$192K |
| 3 |
Bank of New York Mellon
New York
|
+$94.4K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$74.2K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$52.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Broadfin Capital
New York
|
-$1.88M |
| 2 |
Stonepine Capital Management
Bend,
Oregon
|
-$1.29M |
| 3 |
J. Goldman & Co
New York
|
-$1.14M |
| 4 |
CVI Holdings
Wilmington,
Delaware
|
-$991K |
| 5 |
Millennium Management
New York
|
-$382K |
MTNB Hedge Fund Activity: Q2 2019 in Review
45 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2019, worth a combined $27.7M — down 33% from $41.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of MTNB and 5 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $1.36M. The largest seller was Broadfin Capital, cutting an estimated $1.88M.
- 45 institutional investors held Matinas BioPharma (MTNB) as of Q2 2019, down from 52 in Q1 2019.
- Funds reported $27.7M of Matinas BioPharma stock for Q2 2019, down 33% quarter-over-quarter.
- 5 funds opened new Matinas BioPharma positions in Q2 2019 and 12 closed out, a net change of -7 holders.
- The largest Matinas BioPharma buyer in Q2 2019 was Vanguard Group, an estimated $1.36M added.
- The largest Matinas BioPharma seller in Q2 2019 was Broadfin Capital, an estimated $1.88M sold.
Based on aggregated 13F filings for Q2 2019.